HIV Antibody-Only therapy falls short in Long-Term trial
NCT ID NCT02355184
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a single antibody called PRO 140 could keep HIV under control in 20 adults who had been stable on standard combination therapy. Participants stopped their usual HIV pills and received only PRO 140 infusions. The trial was stopped early, and the main goal was to see how long it took for the virus to come back. This approach aims to simplify HIV treatment but still requires ongoing medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CD01-Extension Investigational Site
San Francisco, California, 94115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Faith-Based therapy aims to heal trauma in young women
- Bringing HIV care to the community: a new test in zambia
- Could intense workouts reverse cognitive decline in older HIV patients?